Pharvaris (PHVS) Receivables Refunds (2023 - 2026)
Pharvaris (PHVS) reported Receivables Refunds of $4.7 million for Q1 2026, up 116.41% on a YoY basis from $2.2 million in Q1 2025, and up 0.86% quarter-over-quarter from $4.6 million in Q4 2025.
Pharvaris (PHVS) Receivables Refunds (2023 - 2026) Analysis & Trends
Pharvaris has reported Receivables Refunds for 4 years, with the latest figure at $4.7 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables Refunds rose 116.41% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (up 116.41% YoY), and the FY2025 full-year result was $4.5 million, up 67.68% from the prior year.
- Receivables Refunds for Q1 2026 stood at $4.7 million, up from $4.6 million in the prior quarter.
- The five-year high for Receivables Refunds was $4.7 million in Q1 2026, with the low at $23028.0 in Q3 2023.
- Historically, Receivables Refunds has averaged $2.2 million across 4 years, with a median of $2.3 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables Refunds surged 9842.39% — and 2025, when it rose 29.55%.
- Pharvaris' Receivables Refunds stood at $662281.9 in 2023, then jumped by 301.23% to $2.7 million in 2024, then surged by 74.98% to $4.6 million in 2025, then advanced by 0.86% to $4.7 million in 2026.
- The last three Receivables Refunds figures came in at $4.7 million (Q1 2026), $4.6 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | 4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.69 Mn |
| Dec 31, 2025 | 4.65 Mn |
| Sep 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 2.34 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 520,940.89 |
| Dec 31, 2023 | 662,281.90 |
| Sep 30, 2023 | 23,028.04 |